Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
CapZ-α1 CRISPR/Cas9 KO Plasmid (h): sc-405348
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- CapZ-α1 CRISPR/Cas9 Knockout (KO) Plasmid (h) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
- gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the CapZ-α1 genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
- The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: CapZ-α1 Antibody (2): sc-130309
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
CapZ-α1 CRISPR/Cas9 KO Plasmid (h) | sc-405348 | 20 µg | $397.00 |
Overview
CAPZA1 encodes the alpha-1 subunit of the actin filament capping protein CapZ, a heterodimer that binds the barbed ends of F-actin to regulate filament elongation, turnover, and network architecture. By controlling actin dynamics, CapZ-α1 contributes to cytoskeletal remodeling processes that underpin cell shape, adhesion, and motility, and it interfaces with signaling pathways linked to actin organization and mechanotransduction. Altered regulation of actin capping and associated cytoskeletal programs is frequently implicated in phenotypes relevant to tumor cell invasion, cardiomyocyte structure and contractility, and other contexts where actin-dependent remodeling is a key determinant of cell behavior.
CapZ-α1 CRISPR/Cas9 KO Plasmid (h) is a pool of plasmids designed for targeted disruption of the CAPZA1 gene in human cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the CAPZA1 together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the CAPZA1 open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish CapZ-α1 protein expression.
This CRISPR knockout system enables efficient generation of CAPZA1-deficient cell models for investigation of CapZ-α1 signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
Key Features
- sgRNAs targeting CAPZA1 exon(s) critical for CapZ-α1 function
- Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
- GFP reporter for identification of transfected cells
- Pool of plasmids targeting multiple CAPZA1 genomic sites to improve knockout efficiency
- Compatible with delivery by transfection
Design Variants
CRISPRs +/- HDRs
- gRNAs encoded by CapZ-α1 CRISPR/Cas9 KO Plasmid (h) and CapZ-α1 CRISPR/Cas9 KO Plasmid (h2) target distinct sites within the CAPZA1 locus. One or both targeting designs may be available. See Related Products for availability.
- HDR donor constructs encoded by CapZ-α1 HDR Plasmid (h) and CapZ-α1 HDR Plasmid (h2) contain a puromycin resistance cassette and an RFP reporter flanked by CAPZA1 homology arms to support homology-directed repair at defined CAPZA1 target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.